Date: September 01, 2026
Regulatory Compliance Update
Caplin Point Laboratories Limited has intimated the stock exchanges under Regulation 30 of SEBI LODR Regulations that its subsidiary, Caplin One Labs Limited (COL), has received confirmation of compliance with Good Manufacturing Practices (GMP) from INVIMA (Instituto Nacional de Vigilancia de Medicamentosy Alimentos), Colombia.
INVIMA is the regulatory authority designated by the Ministry of Health and Social Protection of the Republic of Colombia. The regulatory body concluded that COL's manufacturing unit complies with GMP requirements for the manufacture of oncology drug products.
Facility Details
The certified manufacturing unit is located at:
Survey No. 499/-, 88/-, 500/-, 89/1, Plot No. G-44, G-45 & G-46, Block A and Block B
SIDCO Industrial Estate, Kakkalur
Tiruvallur District, Tamil Nadu, India
Product Categories Certified
The GMP compliance certification covers the following oncology drug product categories:
- Sterile dosage forms: Lyophilized powder for injection (in vials)
- Non-sterile dosage forms: Tablets (Coated and Uncoated), Hard capsules
Certification Status
The formal certificate from INVIMA is expected to be received in due course. The company has received confirmation of compliance, with the formal certificate to follow.